Charpidou A - Search Results

1

Voudouri D, Nikolaou V, Laschos K, Charpidou A, Soupos N, Triantafyllopoulou I, Panoutsopoulou I, Aravantinos G, Syrigos K, Stratigos A. Voudouri D, et al. Among authors: charpidou a. Curr Probl Cancer. 2017 Nov-Dec;41(6):407-412. doi: 10.1016/j.currproblcancer.2017.10.003. Epub 2017 Oct 18. Curr Probl Cancer. 2017. PMID: 29096940

2

Developments in the treatment of non-small cell lung cancer.

Gkiozos I, Charpidou A, Syrigos K. Gkiozos I, et al. Among authors: charpidou a. Anticancer Res. 2007 Jul-Aug;27(4C):2823-7. Anticancer Res. 2007. PMID: 17695454 Free article. Review.

3

Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study.

Syrigos KN, Konstantinou M, Sepsas E, Papamichales G, Loullias A, Belenis I, Skottis I, Charpidou A, Roussos C. Syrigos KN, et al. Among authors: charpidou a. Anticancer Res. 2007 Jul-Aug;27(4C):2887-92. Anticancer Res. 2007. PMID: 17695466 Free article. Clinical Trial.

4

Review. EGFR mutations in non-small cell lung cancer--clinical implications.

Charpidou A, Blatza D, Anagnostou V, Syrigos KN. Charpidou A, et al. In Vivo. 2008 Jul-Aug;22(4):529-36. In Vivo. 2008. PMID: 18712184 Free article. Review.

5

Therapy-induced toxicity of the lungs: an overview.

Charpidou AG, Gkiozos I, Tsimpoukis S, Apostolaki D, Dilana KD, Karapanagiotou EM, Syrigos KN. Charpidou AG, et al. Anticancer Res. 2009 Feb;29(2):631-9. Anticancer Res. 2009. PMID: 19331213 Free article. Review.

6

Pneumonitis related to docetaxel: case report and review of the literature.

Alsamarai S, Charpidou AG, Matthay RA, Confeld D, Syrigos KN, Saif MW. Alsamarai S, et al. Among authors: charpidou ag. In Vivo. 2009 Jul-Aug;23(4):635-7. In Vivo. 2009. PMID: 19567400 Free article. Review.

7

Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors.

Kotteas EA, Charpidou AG, Syrigos KN. Kotteas EA, et al. Among authors: charpidou ag. Anticancer Drugs. 2010 Feb;21(2):151-68. doi: 10.1097/CAD.0b013e328334da02. Anticancer Drugs. 2010. PMID: 20016368 Review.

8

Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.

Tourkantonis I, Makrilia N, Ralli M, Alamara C, Nikolaidis I, Tsimpoukis S, Charpidou A, Kotanidou A, Syrigos K. Tourkantonis I, et al. Among authors: charpidou a. Am J Clin Oncol. 2011 Feb;34(1):38-42. doi: 10.1097/COC.0b013e3181cae90e. Am J Clin Oncol. 2011. PMID: 20142722 Clinical Trial.

9

Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.

Charpidou A, Tsagouli S, Tsimpoukis S, Vassias A, Makrilia N, Stratakos G, Gkiozos I, Syrigos K. Charpidou A, et al. Anticancer Drugs. 2010 Jul;21(6):651-5. doi: 10.1097/CAD.0b013e3283393718. Anticancer Drugs. 2010. PMID: 20386306 Clinical Trial.

10

Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients.

Charpidou A, Gkiozos I, Konstantinou M, Eleftheraki A, Demertzis P, Harrington K, Polyzos A, Syrigos KN. Charpidou A, et al. Cancer Lett. 2011 May 28;304(2):144-53. doi: 10.1016/j.canlet.2011.02.018. Cancer Lett. 2011. PMID: 21396771 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page